BlackThorn Therapeutics nets $14 mln Series A
South San Francisco-based BlackThorn Therapeutics, a treatment developer for neurobehavioral disorders, has raised an additional $14 million in Series A funding. The investors in this round were GV and Biomatics Capital.
5 January 2017•1 min read
